Clinical Trials Browser

Interventional × Immunoglobulin Light-chain Amyloidosis × isatuximab × Clear all

Immunoglobulin Light-chain Amyloidosis

NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

NCT05066607 2024-03-06

IsAMYP

Phase 2 Unknown

46 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Clinical Trials

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

IsAMYP